FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection By Ogkologos - January 14, 2026 267 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for safety and efficacy is based on the findings from the PALOMA-3 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Cooperativity of BRAF/MAPK Pathway Inhibition and Immune Checkpoint Blockade in Patients... February 3, 2023 Sing Anyway May 5, 2021 Fisioterapeutas en oncología October 12, 2021 Adjuvant Capecitabine-Containing Regimen Improves Modestly Overall Survival in Patients with Early... January 18, 2022 Load more HOT NEWS Nous-209 Efficiently Stimulates Immunity Against Neoantigens in Lynch Syndrome Carriers Food for Thought: A Fresh Perspective on Nutrition Doctor Said Her Mammogram Results Were Normal, But Now She’s Fighting... Former WNBA Player, Current Georgia Tech Coach Tasha Butts Diagnosed with...
